Skip to main content
Equibles
CSTL logo

CSTL · Castle Biosciences Inc · Earnings Call Transcripts & Audio

Track CSTL — free

Use CSTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.33 +0.01 (+0.03%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$987.67M
Shares
30.55M

Castle Biosciences Inc Earnings Call Transcripts

Quarterly earnings calls for Castle Biosciences Inc (CSTL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲57.7% $37.01M −$20.25M '22 Q3 22-11-02 ▲53.1% $38.34M −$20.62M '22 Q4 23-01-09 ▲56.6% $42.04M −$29.20M '23 Q1 23-05-03 ▲43.9% $50.14M −$18.78M '23 Q2 23-08-02 ▲66.1% $61.49M −$6.91M '23 Q3 23-11-02 ▲72.5% $66.12M −$2.58M '23 Q4 24-02-28 ▲73.6% $72.97M −$2.53M '24 Q1 24-05-02 ▲73.5% $87.00M $8.92M '24 Q2 24-08-05 ▲39.5% $85.78M $2.27M '24 Q3 24-11-04 ▲30.5% $86.31M $9.59M '24 Q4 25-02-27 ▲20.6% $87.99M −$25.85M '25 Q1 25-05-05 ▼0.9% $86.19M $4.52M '25 Q2 25-08-04 ▼3.2% $83.04M −$501,000 '25 Q3 25-11-03 ▲0.8% $87.01M −$2.33M '25 Q4 26-02-26 ▼4.9% $83.68M −$14.52M '26 Q1 26-05-06 LATEST ▲20.1% $103.55M −$2.06M '26 Q2 26-07-30
Conference
Investor event
2026-09-15
Castle Biosciences Inc (CSTL) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Castle Biosciences Inc (CSTL) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Castle Biosciences Inc (CSTL) Q2 2026 Earnings Call Transcript
Confident tone TissueCypher volume growth and ASP Advance ADx reimbursement and launch DecisionDx Melanoma growth
Revenue
$103.55M
▲ 20.1% YoY
Diluted EPS
$-0.07
▼ 146.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Castle Biosciences Inc (CSTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Castle Biosciences Inc (CSTL) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and guidance raise FDA submission timeline for melanoma test Advanced ADTx (atopic dermatitis) ramp
Revenue
$83.68M
▼ 4.9% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Transcript
Confident tone Financial performance and 2026 outlook TissueCypher growth in gastroenterology DecisionDx-Melanoma performance and adoption
Revenue
$87.01M*
▲ 0.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Transcript
Confident tone AdvanceAD-Tx launch in atopic dermatitis Q3 financial performance TissueCypher (Barrett's esophagus) growth
Revenue
$83.04M
▼ 3.2% YoY
Diluted EPS
$-0.02
▼ 125% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Transcript
Confident tone DecisionDx-SCC reimbursement and Novitas LCD Pipeline and M&A (SciBase and Previse) DecisionDx-Melanoma performance and growth
Revenue
$86.19M
▼ 0.9% YoY
Diluted EPS
$0.15
▼ 51.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Transcript
Confident tone Previse Acquisition / GI Pipeline Financial Performance DecisionDx-Melanoma
Revenue
$87.99M
▲ 20.6% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Transcript
Balanced tone DecisionDx-SCC reimbursement and Novitas LCD risk DecisionDx-Melanoma volume and penetration Balance sheet and financial strength
Revenue
$86.31M*
▲ 30.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Transcript
Confident tone Novitas Medicare Reimbursement Review for SCC DecisionDx-Melanoma Performance and Evidence DecisionDx-SCC Test Momentum
Revenue
$85.78M
▲ 39.5% YoY
Diluted EPS
$0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Transcript
Confident tone DecisionDX-SCC growth and ART utility DecisionDX-Melanoma performance and clinical evidence Commercial payer coverage dynamics
Revenue
$87.00M
▲ 73.5% YoY
Diluted EPS
$0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Castle Biosciences Inc (CSTL) Q1 2024 Earnings Call Transcript
Confident tone Clinical evidence and publications TissueCypher Barrett's esophagus test MolDX LCD process for SCC
Revenue
$72.97M
▲ 73.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Castle Biosciences Inc (CSTL) Q4 2023 Earnings Call Transcript
Confident tone Revenue and volume growth DecisionDx-SCC adoption and growth DecisionDx-melanoma clinical evidence
Revenue
$66.12M*
▲ 72.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Castle Biosciences Inc (CSTL) Q3 2023 Earnings Call Transcript
Revenue
$61.49M
▲ 66.1% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Castle Biosciences Inc (CSTL) Q2 2023 Earnings Call Transcript
Revenue
$50.14M
▲ 43.9% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Castle Biosciences Inc (CSTL) Q1 2023 Earnings Call Transcript
Revenue
$42.04M
▲ 56.6% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Castle Biosciences Inc (CSTL) Q4 2022 Earnings Call Transcript
Revenue
$38.34M*
▲ 53.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Castle Biosciences Inc (CSTL) Q3 2022 Earnings Call Transcript
Revenue
$37.01M
▲ 57.7% YoY
Diluted EPS
$-0.77
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Castle Biosciences Inc (CSTL) Q2 2022 Earnings Call Transcript
Revenue
$34.84M
▲ 53.1% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Castle Biosciences Inc (CSTL) Q1 2022 Earnings Call Transcript
Revenue
$26.85M
▲ 17.7% YoY
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Castle Biosciences Inc (CSTL) Q4 2021 Earnings Call Transcript
Revenue
$25.04M*
▲ 44.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Castle Biosciences Inc (CSTL) Q3 2021 Earnings Call Transcript
Revenue
$23.48M
▲ 54.3% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Castle Biosciences Inc (CSTL) Q2 2021 Earnings Call Transcript
Revenue
$22.76M
▲ 79% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Castle Biosciences Inc (CSTL) Q1 2021 Earnings Call Transcript
Revenue
$22.81M
▲ 31% YoY
Diluted EPS
$-0.17
▼ 666.7% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Castle Biosciences Inc (CSTL) Q4 2020 Earnings Call Transcript
Revenue
$17.30M
▼ 1.9% YoY
Diluted EPS
$-0.23
▼ 309.1% YoY
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Castle Biosciences Inc (CSTL) Q3 2020 Earnings Call Transcript
Revenue
$15.22M
▲ 3% YoY
Diluted EPS
$-0.23
▼ 560% YoY
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Castle Biosciences Inc (CSTL) Q2 2020 Earnings Call Transcript
Revenue
$12.71M
▲ 18.4% YoY
Diluted EPS
$-0.08
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Castle Biosciences Inc (CSTL) Q1 2020 Earnings Call Transcript
Revenue
$17.42M
▲ 99.8% YoY
Diluted EPS
$0.03
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-09
Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call
Revenue
$17.64M
▲ 54.2% YoY
Diluted EPS
$0.11
▼ 71.1% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 1447362 CUSIP 14843C105 13F (30d) 52 filings 52 filers Visit website Investor relations